Navigation Links
Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
Date:6/6/2011

SAN DIEGO and FOSTER CITY, Calif., June 6, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) in the development of a subcutaneous (under the skin) injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT). Under terms of the agreement, Halozyme may receive up to $63 million, commencing with an upfront payment of $9 million and total potential future milestone payments of $54 million dependent upon the achievement of clinical and regulatory targets, plus up to 11% royalty on future sales of the combination of rHuA1AT with rHuPH20. The license provides Intrexon Corporation, a next generation synthetic biology company, with exclusivity to alpha 1-antitrypsin, for the indications resulting from A1AT deficiency. Additional terms of the transaction have not been disclosed.

(Logo:  http://photos.prnewswire.com/prnh/20110606/LA14886LOGO)

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

Alpha 1-antitrypsin is a protease inhibitor that provides a protective effect from inflammatory cell proteases, especially neutrophil elastase. Intrexon is using its synthetic DNA platform for high-level expression of recombinant A1AT for the potential treatment of diseases resulting from genetic alpha 1-antitrypsin deficiency such as genetic emphysema. A1AT may also benefit patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Currently there is no A1AT recombinant protein available and,
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
2. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
3. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
4. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
6. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
7. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
8. Halozyme Therapeutics Realigns Management
9. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
10. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
11. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 13, 2014 Auf ... Tokio veranstalteten F&E-Tagung meldete Astellas ... Neuausrichtung seines Forschungsrahmenprogramms. Die Tagung bot Astellas ... fortgeschrittenen klinischen Programme und die Konzernstrategie des ... bestand darin, aktuelle Meldungen zu den Astellas-Initiativen ...
(Date:7/13/2014)... 2014  Eli Lilly and Company (NYSE: ... non-clinical study in genetically engineered mice examining combination ... antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data ... in removing clumps of amyloid-beta protein in the ... lead to Alzheimer,s disease (AD) – than use ...
(Date:7/11/2014)... ANGELES , July 11, 2014 /PRNewswire-iReach/ -- ... e-liquid, a vegetable-glycol solution for use in portable ... of the active ingredients in cannabis, cannabidiol offers ... personal vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) today announced its financial ... quarter of 2008, the Company reported a,net loss of $21.1 ... of,$25.7 million, or $(0.68) per share, for the same period ... were $1.8 million compared with,$0.1 million for the same period ...
... April 30 CureDM, Inc., a,biopharmaceutical company developing ... 1 and 2 diabetes, announces its,achievement of a ... CureDM has successfully stabilized HIP to improve its,bioavailability ... used in man may be as much as ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2008 Results 2Neurocrine Biosciences Reports First Quarter 2008 Results 3Neurocrine Biosciences Reports First Quarter 2008 Results 4Neurocrine Biosciences Reports First Quarter 2008 Results 5Neurocrine Biosciences Reports First Quarter 2008 Results 6Neurocrine Biosciences Reports First Quarter 2008 Results 7Neurocrine Biosciences Reports First Quarter 2008 Results 8CureDM's Diabetes Therapy Achieves Major Development Milestone 2
(Date:7/13/2014)... Ticket Down is a reliable source for ... fifth straight year (and second under the current name), the ... this summer. The tournament features eight club teams from around ... split into two groups of four and upon the completion ... to become champion. One team that has had the most ...
(Date:7/13/2014)... 2014 Carolinas Healthcare System celebrated today ... Carolinas HealthCare System - Anson located in Anson County. ... Community Hospital in Wadesboro. , Located on U.S. Highway ... the previous facility. Situated on a 10-acre site, the ... emergency room drop-off, helipad, healing garden, and 15 beds. ...
(Date:7/13/2014)... Intraocular Lens (IOL) Market: Global Industry ... 2019 , Intraocular lens (IOL) is inserted in the ... The lenses are inserted inside the eye, after removal ... replaces the focusing power of natural lens. The pseudophakic ... deliver the light focusing function which was originally undertaken ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic and ... esophagitis (EoE), opening up potential new therapeutic strategies ... , EoE is a chronic inflammatory disorder of ... hypersensitivity to certain foods and an over-accumulation in ... (part of the body,s immune system). EoE can ...
(Date:7/13/2014)... for diagnosing type-1 diabetes could improve patient care ... according to the device,s inventors at the Stanford ... paper to be published online July 13 in ... to detect type-1 diabetes outside hospital settings. The ... of diabetes mellitus, which are both characterized by ...
Breaking Medicine News(10 mins):Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4
... EPIDEMIC ABROADMENLO PARK, Calif., May 7 Two-thirds of ... government funding to improve health in developing countries, while ... spending too much on global health, according to a ... towards U.S. global health and development assistance. Levels ...
... better than no treatment at all, study shows , , ... essential for reducing the risk of heart disease and ... matter of debate. , Now, two new analyses attempt ... attacks, all antihypertensive drugs work, with the exception of ...
... million adultsor one fourth of the people in the ... and this undiagnosed population accounts for an estimated $18 ... a study in a recent issue of Population ... Ann Liebert, Inc. ( www.liebertpub.com ). The article is ...
... of Illinois at Chicago has received nearly $1 million ... to study the benefits of green healthy housing. , ... and Reinvestment Act of 2009. , UIC researchers will ... move from distressed, unhealthy public housing into green, affordable, ...
... Results in New Compounded Medication Program GLEN BURNIE, ... largest practice-to-home delivery veterinary pharmacy today announced the ... than 1,200 pet owners from across the U.S.Key ... about having convenient services and options that help ...
... Pharma GmbH received an Orphan Drug Designation (ODD) by ... the EMEA for inhaled PARI Tobramycin 100 delivered via ... the second ODD designation that PARI Pharma has received ... first ODD was granted for PARI,s inhaled cyclosporine delivered ...
Cached Medicine News:Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 2Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 3Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 4Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 5Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 6Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 2Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 3Health News:UIC receives $1M HUD grant to study green healthy housing 2Health News:VetCentric Releases Findings of Pet Owner Survey 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 3Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 4
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... The Sysmex pocH-100i is the first ... with low daily testing requirements. With its ... 3-part differential from just 15 L of ... for any small healthcare site including the ...
Medicine Products: